Ticagrelor and prasugrel are being evaluated for comparative efficacy in reducing ischemic complications in STEMI patients, but the abstract does not report the study results.
Absolute Event Rate: 0% vs 0%
Ticagrelor and prasugrel are guideline-recommended class I antiplatelet agents for patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Despite their widespread use, there is uncertainty regarding their relative efficacy in reducing ischemic complications. This meta-analysis aims to evaluate the efficacy of ticagrelor compared with prasugrel in STEMI.
Kayani et al. (Wed,) reported a other. Ticagrelor and prasugrel are being evaluated for comparative efficacy in reducing ischemic complications in STEMI patients, but the abstract does not report the study results.